Semaglutide May Aid Stroke Recovery in Some Patients

What This Study Is About

Researchers in China tested whether semaglutide — the active ingredient in Ozempic and Wegovy — could help people recover better after a severe type of stroke called a large vessel occlusion (LVO).

What Is a Large Vessel Occlusion Stroke?

An LVO stroke happens when a major artery in the brain becomes completely blocked. It is one of the most serious types of stroke and often causes significant disability. The main treatment is a procedure called endovascular therapy (EVT), where doctors physically remove the clot from the blood vessel.

How the Study Worked

Between August 2023 and July 2024, 140 stroke patients were randomly split into two groups:

• Semaglutide group (69 patients): Received a 0.5 mg injection of semaglutide before and one week after their stroke procedure.
• Standard care group (71 patients): Received usual stroke treatment only.

The main goal was to see how many patients had a good neurological recovery — meaning they could largely care for themselves — 90 days after their stroke.

What the Researchers Found

Overall, the recovery rates were similar between both groups:

• 56.5% of semaglutide patients achieved good recovery
• 54.9% of standard care patients achieved good recovery

This difference was not statistically significant, meaning it could be due to chance.

An Important Subgroup Finding

However, researchers noticed something interesting: semaglutide appeared to work differently depending on whether patients also received a clot-dissolving drug called intravenous thrombolysis (IVT). Among patients who did not receive the clot-dissolving drug:

• 64.7% of semaglutide patients had good recovery
• 44.1% of standard care patients had good recovery

This is a meaningful difference, though researchers caution it needs to be confirmed in larger studies.

Was Semaglutide Safe?

Yes. No serious side effects were linked to semaglutide treatment in this trial, which is an important finding for a medication being tested in stroke patients.

What This Means for Patients

This was a Phase 2 trial — an early-stage study designed mainly to test safety and gather preliminary data. The results are promising but not yet conclusive. A larger Phase 3 trial will be needed to confirm whether semaglutide should become a standard part of stroke care.